Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations

Individuals who had preoperative percutaneous transthoracic needle biopsy (PTNB) had an increased risk of local-regional recurrence in non–small cell lung cancer (NSCLC).

A review found that assessing for health-related quality of life (HRQOL) was not frequently done in studies related to non–small cell lung cancer (NSCLC).

Aumolertinib was compared against osimertinib to demonstrate its efficacy in those with mutated non-small cell lung cancer (NSCLC).

Adverse events related to the immune system tended to accumulate over time when patients used immune checkpoint inhibitors (ICIs) over time.

Amivantamab plus lazertinib enhances survival in NSCLC but requires complex care compared with osimertinib, explained Danny Nguyen, MD, of City of Hope.

The approval allows all patients 12 years and older to use pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection for solid tumor indications approved for intravenous pembrolizumab.